Medtronic plc
 (MDT)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Dec. 3, 2015, 7:45 AM
    • Medtronic (MDT -0.5%) FQ2 results: Revenues: $7,058M (+61.7%); R&D Expense: $545M (+45.7%); SG&A: $2,343M (+55.5%); Operating Income: $1,300M (+26.2%); Net Income: $520M (-37.2%); EPS: $0.36 (-56.6%); Non-GAAP EPS: $1.03 (+1.0%); Quick Assets: $2,378M (-50.9%).
    • Segment Revenues: Cardiac Rhythm & Heart Failure: $1,324M (+0.3%); Coronary & Structural Heart: $754M (+1.5%); Aortic & Peripheral Vascular: $404M (+81.2%); Surgical Solutions: $1,291M; Patient Monitoring & Recovery: $1,065M; Spine: $719M (-3.6%); Neuromodulation: $482M (-2.4%); Surgical Technologies: $426M (+3.9%); Neurovascular: $143M; Diabetes Group: $450M (+4.7%).
    • FY2016 Guidance: Non-GAAP EPS: $4.33 - 4.40.
    | Dec. 3, 2015, 7:45 AM
  • Dec. 3, 2015, 7:17 AM
    • Medtronic (NYSE:MDT): FQ2 EPS of $1.03 beats by $0.03.
    • Revenue of $7.06B (+61.6% Y/Y) in-line.
    • Press Release
    | Dec. 3, 2015, 7:17 AM | 2 Comments
  • Sep. 3, 2015, 7:42 AM
    • Medtronic (NYSE:MDT) fiscal Q1 results ($M): Total Revenues: 7,274 (+70.2%); Cardiac Rhythm & Heart Failure: 1,369 (+9.0%); Coronary & Structural Heart: 788 (+2.9%); Aortic & Peripheral Vascular: 410 (+76.7%); Cardiac & Vascular Group: 2,567 (+13.9%); Minimally Invasive Therapies Group: 2,456; Spine: 763 (+2.7%); Neuromodulation: 485 (+2.7%); Surgical Technologies: 485 (+1.3%); Neurovascular: 138; Restorative Therapies: 1,806 (+12.7%); Diabetes Group: 445 (+7.0%).
    • Net Income: 820 (-5.9%); EPS: 0.57 (-34.5%); CF Ops: 816 (+163.2%).
    • Fiscal 2016 Guidance: Revenue Growth: 4 - 6% (unch); Non-GAAP EPS: $4.30 - 4.40 (unch).
    | Sep. 3, 2015, 7:42 AM
  • Sep. 3, 2015, 7:22 AM
    • Medtronic (NYSE:MDT): FQ1 EPS of $1.02 beats by $0.01.
    • Revenue of $7.27B (+70.3% Y/Y) beats by $220M.
    | Sep. 3, 2015, 7:22 AM | 3 Comments
  • Sep. 2, 2015, 5:30 PM
  • Sep. 2, 2015, 12:40 PM
    • Medtronic (MDT +1.8%) will report fiscal Q1 results tomorrow before the open. Consensus view is EPS of $1.01 on revenues of $7.05B. In June, the company provided earnings guidance of $1.08 - 1.13.
    | Sep. 2, 2015, 12:40 PM
  • Jun. 2, 2015, 8:00 AM
    • Medtronic (NYSE:MDT) fiscal Q4 results ($M): Revenues: 7,304 (+60.0%); Cardiac Rhythm & Heart Failure: 1,398 (+3.9%); Coronary & Structural Heart: 792 (+1.1%); Aortic & Peripheral Vascular: 406 (+69.2%); Cardiac & Vascular Group: 2,596 (+9.6%); Minimally Invasive Therapies Group: 2,387; Surgical Solutions: 1,293; Patient Monitoring & Recovery: 1,094; Spine: 743 (-5.5%); Neuromodulation: 518 (+1.0%); Surgical Technologies: 461 (+5.3%); Neurovascular: 132; Restorative Therapies: 1,854 (+6.7%); Diabetes Group: 467 (+1.5%).
    • Net Income: -1 (-100.2%); EPS: 0.00 (-100.0%); CF Ops: 1,912 (+44.0%).
    • Fiscal 2016 Guidance: Revenue growth: 4 - 6%; Non-GAAP EPS: $4.30 - 4.40.
    • Fiscal Q1 Guidance: Non-GAAP EPS: $1.08 - 1.13.
    | Jun. 2, 2015, 8:00 AM
  • Jun. 2, 2015, 7:25 AM
    • Medtronic (NYSE:MDT): FQ4 EPS of $1.16 beats by $0.05.
    • Revenue of $7.3B (+59.7% Y/Y) beats by $110M.
    | Jun. 2, 2015, 7:25 AM
  • Jun. 1, 2015, 5:30 PM
  • May 19, 2015, 9:03 AM
    • Medtronic (NYSE:MDT) preliminary Q4 results ($M): Total Revenues: 7,302 (+59.9%); Cardiac Rhythm & Heart Failure: 1,398 (+3.9%); Coronary & Structural Heart: 792 (+1.1%); Aortic & Peripheral Vascular: 406 (+69.2%); Cardiac & Vascular Group: 2,596 (+9.6%); Minimally Invasive Therapies Group: 2,385; Spine: 743 (-5.5%); Neuromodulation: 518 (+1.0%); Surgical Technologies: 461 (+5.3%); Neurovascular: 132; Restorative Therapies Group: 1,854 (+6.7%); Diabetes Group: 467 (+1.5%).
    • This is the first quarter that includes Covidien so final results will be reported two weeks later than normal on June 2.
    | May 19, 2015, 9:03 AM | 1 Comment
  • Feb. 17, 2015, 8:13 AM
    • Medtronic (NYSE:MDT) fiscal Q3 results ($M): Total Revenues: 4,318 (+3.7%); Cardiac Rhythm & HF: 1,269 (+7.2%), High Power: 650 (-0.8%), Low Power: 489 (+11.4%), AF & Other: 130 (+44.4%); Coronary & Structural Heart: 737 (+2.8%), Coronary: 407 (-6.7%), Structural Heart: 330 (+17.4%); Aortic & Peripheral Vascular: 218 (0.0%); Cardiac & Vascular Group: 2,224 (+5.0%); Spine: 740 (-0.5%), Core Spine: 543 (-2.0%), Interventional Spine: 75 (-2.6%), BMP: 122 (-0.5%); Neuromodulation: 487 (+1.9%); Surgical Technologies: 418 (+8.3%).
    • COGS: 1,128 (+7.4%); R&D Expense: 373 (+3.6%); SG&A Expense: 1,487 (+2.3%); Net Income: 977 (+28.2%); EPS: 0.98 (+30.7%); CF Ops: (+9.6%), Quick Assets: 17,231 (+26.1%).
    • Gross Profit: 3,190 (+2.5%); COGS: 26.1% (+3.6%); Gross Margin: 73.9% (-1.2%); Operating Earnings: 1,330 (+2.4%); Operating Earnings Yield: 30.8% (-1.3%); Net Earnings Yield: 22.6% (+23.6%).
    • CF Ops last three quarters: 310, 913, 1767.
    • Fiscal Q4 Guidance: Revenue growth: 4 - 6%.
    • Shares are up 3% premarket on increased volume.
    | Feb. 17, 2015, 8:13 AM
  • Feb. 17, 2015, 7:43 AM
    • Medtronic (NYSE:MDT): FQ3 EPS of $1.01 beats by $0.04.
    • Revenue of $4.32B (+3.8% Y/Y) beats by $70M.
    • Shares +0.12% PM.
    | Feb. 17, 2015, 7:43 AM | 2 Comments
  • Feb. 16, 2015, 5:30 PM
  • Feb. 11, 2015, 4:11 PM
    • Medtronic (NYSE:MDT) will report fiscal Q3 results on February 17 before the open. The conference call will begin at 7:00 am CT/8:00 am ET.
    • Consensus view is EPS of $0.97 on revenues of $4.3B.
    | Feb. 11, 2015, 4:11 PM
  • Jan. 22, 2015, 8:38 AM
    • Covidien (COV) FQ1 results: Revenues: $2,686M (+1.8%), Advanced Surgical: $928M (+8.8%), General Surgical: $385M (-5.6%), Surgical Solutions: $1,313M (+4.1%), Vascular Therapies: $428M (+0.7%), Respiratory and Patient Care: $945M (-0.8%); COGS: $1,042M (-3.2%); R&D Expense: $133M (+6.4%); SG&A: $865M (+1.8%); Operating Income: $648M (+22.0%); Net Income: $511M (+28.4%); EPS: $1.12 (+28.7%).
    • No guidance given.
    | Jan. 22, 2015, 8:38 AM
Company Description
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.